Synthetic Biologics Inc (NYSEMKT:SYN) announced this morning that the U.S.
Synthetic Biologics Inc (NYSEMKT:SYN) shares were rising almost 29% yesterday as the news took off that the biotech firm won a Breakthrough Therapy …
Investors in Synthetic Biologics Inc (NYSEMKT:SYN) should be smiling from ear to ear today following the news that the FDA has granted a …
Synthetic Biologics Inc (NYSEMKT:SYN) is steaming right along with key programs gearing toward pivotal studies. Despite financing continuing to be the real stand-out …
Synthetic Biologics Inc (NYSEMKT:SYN) revealed Wednesday, January 18th after market close that the FDA has green-lighted its Phase IIb/III adaptive trial design of …
Synthetic Biologics Inc (NYSEMKT:SYN) confirmed plans to initiate a Phase 2b/3 adaptive pivotal trial for SYN-010, the Company’s modified-release reformulation of lovastatin lactone …
After holding a meeting with Synthetic Biologics Inc (NYSEMKT:SYN) management, where an update regarding the company’s clinical development programs was provided, FBR analyst Edward White reiterates an …
Synthetic Biologics Inc (NYSEMKT:SYN) announced positive topline data from its Phase 2b clinical trial for SYN-004 (ribaxamase), the Company’s first-in-class oral enzyme designed to …
Synthetic Biologics Inc (NYSE MKT: SYN) announced that the United States Patent Office has granted U.S.
Synthetic Biologics Inc (NYSEMKT:SYN) announced that it intends to offer and sell, subject to market and other conditions, 25,000,000 shares of its common …
